GSK calls it quits on trade group BIO for 2025, following exits by Takeda, UCB and more

GSK calls it quits on trade group BIO for 2025, following exits by Takeda, UCB and more

Source: 
Fierce Pharma
snippet: 

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), following a string of exits by companies including Pfizer, UCB, WuXi AppTec and Takeda.